HOME >> BIOLOGY >> NEWS
Stanford researchers uncover possible approach to attack HIV-infected cells

STANFORD, Calif. - A drug being tested as a cancer treatment also appears to be effective in the laboratory against HIV, say Stanford University Medical Center researchers. The findings suggest the drug may benefit patients by targeting infected cells without harming the healthy cells the body needs to defend itself against disease. Plans are under way to test the drug in people with the HIV virus.

HIV devastates the body's immune system by taking over and killing a particular class of white blood cells known as CD4+ helper T cells. These cells coordinate the body's defense against foreign invaders. Without the normal array of T cells, HIV patients have weakened immune systems, leaving them susceptible to infections.

Stanford researchers have now found that low doses of the drug called motexafin gadolinium (or Gd-Tex) selectively kills HIV-infected T cells. "Gd-Tex worked in vitro," said Leonard Herzenberg, PhD, professor emeritus of genetics and senior author of the study reported in the Feb. 18 issue of the Proceedings of the National Academy of Sciences. "It selectively killed the HIV-infected cells when they were in a mixture with healthy white blood cells. And to our surprise, only the infected CD4+ T cells were killed."

Gd-Tex is now being tested in humans as a cancer treatment. The drug acts by accumulating in tumor cells and attacking the molecules that normally protect the cells from one type of stress. The cells therefore die more readily during radiation treatment.

When Herzenberg and his wife, Leonore Herzenberg, PhD, professor of genetics, learned about Gd-Tex, they had a hunch that the drug might also be effective in controlling HIV. Earlier studies had shown that the HIV virus attacks the cell's natural defenses against harmful molecules by reducing levels of a protective molecule called glutathione. When glutathione drops below a certain level, the weakened cell gives in to the stress an
'"/>

Contact: Amy Adams
amyadams@stanford.edu
650-723-3900
Stanford University Medical Center
18-Feb-2002


Page: 1 2

Related biology news :

1. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
2. Stanford researchers findings may shed light on common, deadly birth defect
3. Leukemia stem cells identified by Stanford researchers
4. New view of leukemia cells identifies best treatment options, Stanford researchers say
5. Confidentiality of genetic databases questioned by Stanford researchers
6. Stanford researchers go from heaven to Earth in lifeguard test
7. Transplant rejection averted by simple light exposure in Stanford animal study
8. Fat cells heal skull defects in mice, Stanford research shows
9. Gene-based screen sorts cancer cases, say Stanford researchers
10. Elusive but ubiquitous microbe fingered as gum disease culprit in Stanford study
11. Sticklebacks reveal secrets to evolutionary change in Stanford study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/13/2018)... ... November 13, 2018 , ... Pharmafusion LLC ... a featured presenter at the upcoming CBI Gross-to-Net (GTN) Summit in Philadelphia on ... Friday, November 16, where conference attendees will have the opportunity to “test drive” ...
(Date:11/13/2018)... ... November 12, 2018 , ... ... virtual events and webinars, will be hosting its 9th Annual Clinical Diagnostics ... technologies and treatments available, and updates in regulatory processes to ensure patient safety ...
(Date:11/9/2018)... ... November 08, 2018 , ... Boekel ... Heating blocks, also known as dry bath incubators are used in laboratories worldwide ... , For the new heating blocks, Boekel Scientific used the same interface ...
Breaking Biology News(10 mins):
(Date:11/5/2018)... NASHVILLE, Tenn. (PRWEB) , ... November 05, 2018 ... ... Accredited radiology and telemedicine company backed by Siemens Healthineers and several healthcare VC ... blockchain based radiology solution and making a history by purchasing tokens and obtaining ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades has ... Activator Like (TAL) effector code technology for applications in advancing research in epigenetic ... in plants. Since its discovery in 2009, the efficacy of TAL effector-based DNA targeting ...
(Date:11/3/2018)... ... , ... Triangle Insights Group, a premier life sciences consulting firm, announced today ... in the United States, appearing on this year’s Inc. 5000 list. Since its ... growth over the previous three years. , Separately, Triangle Insights was also ranked ...
(Date:10/31/2018)... ... October 30, 2018 , ... ... trial at the Campbell Clinic in Memphis, Tennessee. This study enrolled 125 ... standard of care for managing pain after total knee replacement surgery (TKA). , ...
Breaking Biology Technology:
Cached News: